JPWO2021200857A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021200857A5 JPWO2021200857A5 JP2022512232A JP2022512232A JPWO2021200857A5 JP WO2021200857 A5 JPWO2021200857 A5 JP WO2021200857A5 JP 2022512232 A JP2022512232 A JP 2022512232A JP 2022512232 A JP2022512232 A JP 2022512232A JP WO2021200857 A5 JPWO2021200857 A5 JP WO2021200857A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence represented
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 173
- 229920001184 polypeptide Polymers 0.000 claims 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 239000012634 fragment Substances 0.000 claims 34
- 210000004027 cell Anatomy 0.000 claims 13
- 239000002157 polynucleotide Substances 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010073360 Appendix cancer Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010061825 Duodenal neoplasm Diseases 0.000 claims 2
- 201000005231 Epithelioid sarcoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000000787 conjunctival cancer Diseases 0.000 claims 2
- 201000000312 duodenum cancer Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 230000000762 glandular Effects 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 2
- 206010024627 liposarcoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 208000007538 neurilemmoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 201000005443 oral cavity cancer Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000004846 retroperitoneal sarcoma Diseases 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 206010039667 schwannoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010042863 synovial sarcoma Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 208000037965 uterine sarcoma Diseases 0.000 claims 2
- 206010046885 vaginal cancer Diseases 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- 101100537690 Arabidopsis thaliana TPC1 gene Proteins 0.000 claims 1
- 125000006519 CCH3 Chemical group 0.000 claims 1
- 101150008810 cch1 gene Proteins 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023078244A JP7486759B2 (ja) | 2020-03-30 | 2023-05-11 | 二重特異的抗体 |
| JP2024071827A JP2024102162A (ja) | 2020-03-30 | 2024-04-25 | 二重特異的抗体 |
| JP2026009341A JP2026069551A (ja) | 2020-03-30 | 2026-01-23 | 二重特異的抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020061476 | 2020-03-30 | ||
| JP2020061476 | 2020-03-30 | ||
| PCT/JP2021/013378 WO2021200857A1 (ja) | 2020-03-30 | 2021-03-29 | 二重特異的抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078244A Division JP7486759B2 (ja) | 2020-03-30 | 2023-05-11 | 二重特異的抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021200857A1 JPWO2021200857A1 (https=) | 2021-10-07 |
| JPWO2021200857A5 true JPWO2021200857A5 (https=) | 2023-03-06 |
| JP7285495B2 JP7285495B2 (ja) | 2023-06-02 |
Family
ID=77929191
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512232A Active JP7285495B2 (ja) | 2020-03-30 | 2021-03-29 | 二重特異的抗体 |
| JP2023078244A Active JP7486759B2 (ja) | 2020-03-30 | 2023-05-11 | 二重特異的抗体 |
| JP2024071827A Pending JP2024102162A (ja) | 2020-03-30 | 2024-04-25 | 二重特異的抗体 |
| JP2026009341A Pending JP2026069551A (ja) | 2020-03-30 | 2026-01-23 | 二重特異的抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078244A Active JP7486759B2 (ja) | 2020-03-30 | 2023-05-11 | 二重特異的抗体 |
| JP2024071827A Pending JP2024102162A (ja) | 2020-03-30 | 2024-04-25 | 二重特異的抗体 |
| JP2026009341A Pending JP2026069551A (ja) | 2020-03-30 | 2026-01-23 | 二重特異的抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12344674B2 (https=) |
| EP (1) | EP4144370A4 (https=) |
| JP (4) | JP7285495B2 (https=) |
| KR (1) | KR20220160598A (https=) |
| CN (2) | CN115023500B (https=) |
| AU (1) | AU2021246385A1 (https=) |
| BR (1) | BR112022016695A2 (https=) |
| CA (1) | CA3175577A1 (https=) |
| CO (1) | CO2022013885A2 (https=) |
| IL (1) | IL296514A (https=) |
| MX (1) | MX2022010751A (https=) |
| PH (1) | PH12022500012A1 (https=) |
| TW (1) | TWI865753B (https=) |
| WO (1) | WO2021200857A1 (https=) |
| ZA (1) | ZA202211246B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7674278B2 (ja) * | 2019-07-03 | 2025-05-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法 |
| US20250195645A1 (en) * | 2022-03-16 | 2025-06-19 | Daiichi Sankyo Company, Limited | Combination of multispecific molecule and immune checkpoint inhibitor |
| EP4536839A1 (en) * | 2022-06-09 | 2025-04-16 | Amgen Inc. | Methods of screening for peptide-hla class i alloreactivity |
| CN120077068A (zh) * | 2022-08-18 | 2025-05-30 | 英美偌科有限公司 | 多结构域结合分子 |
| EP4573125A1 (en) * | 2022-08-18 | 2025-06-25 | Immunocore Limited | Multi-domain binding molecules |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| JP2003111595A (ja) | 2001-06-25 | 2003-04-15 | Kyogo Ito | 腫瘍抗原 |
| ATE417065T1 (de) | 2004-05-19 | 2008-12-15 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2010106431A2 (en) * | 2009-03-20 | 2010-09-23 | Ludwig Institute For Cancer Research Ltd | High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| EP2832856A4 (en) | 2012-03-29 | 2016-01-27 | Chugai Pharmaceutical Co Ltd | ANTI-LAMP5 ANTIBODIES AND USE THEREOF |
| RU2639287C2 (ru) * | 2012-06-27 | 2017-12-20 | Ф. Хоффманн-Ля Рош Аг | Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| KR102332303B1 (ko) | 2013-05-31 | 2021-11-26 | 자임워크스 인코포레이티드 | 감소되거나 침묵화된 효과기 기능을 갖는 이종다량체 |
| RU2585091C1 (ru) | 2015-01-19 | 2016-05-27 | государственное бюджетное образовательное учреждение высшего профессионального образования "Кемеровская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ определения антител к аллогенным hla-g |
| HK1248255A1 (zh) * | 2015-06-24 | 2018-10-12 | 优瑞科生物技术公司 | 靶向ny-eso-1肽/mhc复合物的构建体及其用途 |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| JP7202185B2 (ja) | 2016-12-22 | 2023-01-11 | 第一三共株式会社 | 抗ｃｄ３抗体及び該抗体を含む分子 |
| JP2020061476A (ja) | 2018-10-11 | 2020-04-16 | ソニーセミコンダクタソリューションズ株式会社 | 固体撮像装置及び電子機器 |
| JP7674278B2 (ja) | 2019-07-03 | 2025-05-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法 |
-
2021
- 2021-03-29 PH PH1/2022/500012A patent/PH12022500012A1/en unknown
- 2021-03-29 WO PCT/JP2021/013378 patent/WO2021200857A1/ja not_active Ceased
- 2021-03-29 JP JP2022512232A patent/JP7285495B2/ja active Active
- 2021-03-29 IL IL296514A patent/IL296514A/en unknown
- 2021-03-29 MX MX2022010751A patent/MX2022010751A/es unknown
- 2021-03-29 CN CN202180009615.9A patent/CN115023500B/zh active Active
- 2021-03-29 CN CN202510205105.9A patent/CN120058957A/zh active Pending
- 2021-03-29 CA CA3175577A patent/CA3175577A1/en active Pending
- 2021-03-29 BR BR112022016695A patent/BR112022016695A2/pt unknown
- 2021-03-29 KR KR1020227034083A patent/KR20220160598A/ko active Pending
- 2021-03-29 EP EP21782349.1A patent/EP4144370A4/en active Pending
- 2021-03-29 AU AU2021246385A patent/AU2021246385A1/en active Pending
- 2021-03-29 TW TW110111315A patent/TWI865753B/zh active
- 2021-03-29 US US17/799,648 patent/US12344674B2/en active Active
-
2022
- 2022-09-28 CO CONC2022/0013885A patent/CO2022013885A2/es unknown
- 2022-10-13 ZA ZA2022/11246A patent/ZA202211246B/en unknown
-
2023
- 2023-05-11 JP JP2023078244A patent/JP7486759B2/ja active Active
- 2023-05-16 US US18/318,610 patent/US11952423B2/en active Active
-
2024
- 2024-04-25 JP JP2024071827A patent/JP2024102162A/ja active Pending
-
2025
- 2025-05-23 US US19/218,008 patent/US20250282889A1/en active Pending
-
2026
- 2026-01-23 JP JP2026009341A patent/JP2026069551A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021200857A5 (https=) | ||
| IL317587A (en) | Antibody against SIRPalpha | |
| JP2018108081A5 (https=) | ||
| JP2020510422A5 (https=) | ||
| JP2022105495A5 (https=) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2023113950A5 (https=) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2020526478A5 (https=) | ||
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| JP2023527609A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2018504105A5 (https=) | ||
| JP2025092589A5 (https=) | ||
| JP2023538945A5 (https=) | ||
| JP2013056885A5 (https=) | ||
| JP2023081303A5 (https=) | ||
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| RU2018128414A (ru) | Новое psma-связывающее антитело и его применения | |
| JP2010500876A5 (https=) | ||
| RU2019143101A (ru) | Новое анти-с-мет антитело и его применение | |
| JP2024511137A5 (https=) | ||
| RU2009123409A (ru) | Новые антипролиферативные антитела | |
| JP2024109911A5 (https=) |